Loading insider details...
Beta
Latest Form 4 (Mar 23, 2026): Grant/Award of 24,999 ANTX shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Mar 23, 2026 | AN2 Therapeutics, Inc. (ANTX) | Grant/Award | 24,999 | n/a |
| Feb 23, 2026 | AN2 Therapeutics, Inc. (ANTX) | Grant/Award | 20,400 | n/a |
| May 23, 2025 | AN2 Therapeutics, Inc. (ANTX) | Grant/Award | 19,111 | n/a |
| Jun 21, 2024 | AN2 Therapeutics, Inc. (ANTX) | Grant/Award | 64,503 | n/a |
| Jun 10, 2023 | AN2 Therapeutics, Inc. (ANTX) | Grant/Award | 23,742 | n/a |
| Jan 25, 2023 | Calithera Biosciences, Inc. (CALA) | Tax Withholding | 317 | $141.41 |
| May 17, 2022 | AN2 Therapeutics, Inc. (ANTX) | Grant/Award | 10,362 | n/a |
| Jan 27, 2022 | Calithera Biosciences, Inc. (CALA) | Grant/Award | 215,000 | n/a |
| Jan 25, 2022 | Calithera Biosciences, Inc. (CALA) | Tax Withholding | 5,586 | $2.7K |
| Jan 7, 2022 | Calithera Biosciences, Inc. (CALA) | Tax Withholding | 18,077 | $11.9K |